INTRODUCTION AND OBJECTIVES: Immune-checkpoint blockade (ICB) has shown efficacy across multiple malignancies, including clear cell Renal Cell Carcinoma (ccRCC). Biomarkers such as tumor mutation burden (TMB), neoantigen load and zygosity at the HLA class-I loci have been shown to be predictors of response in non-kidney neoplasms. However, they remain unvalidated in ccRCC. We aim to investigate the genomic biomarkers associated with ICB response in this setting.
INTRODUCTION AND OBJECTIVES: Immune-checkpoint blockade (ICB) has shown efficacy across multiple malignancies, including clear cell Renal Cell Carcinoma (ccRCC). Biomarkers such as tumor mutation burden (TMB), neoantigen load and zygosity at the HLA class-I loci have been shown to be predictors of response in non-kidney neoplasms. However, they remain unvalidated in ccRCC. We aim to investigate the genomic biomarkers associated with ICB response in this setting.
METHODS: Whole exome sequencing (WES) was performed on 27 pretreatment tumor derived DNA samples from patients treated at our institution. Additionally, data from 75 treated patients was obtained from publicly available WES datasets. Somatic mutations, TMB, neoantigen load, and HLA zygosity were called and analyzed with respect to objective response rate (ORR), progression free survival (PFS), and overall survival (OS) estimates. Continuous covariates were categorized into high and low groups using the median cut-off value for each parameter. All the data was processed using our previously-validated pipeline and commonly-used computational tools. Survival estimates were computed using the Kaplan-Meier method. A pre-rejection alpha level of 0.05 was set in advance of the analyses.
RESULTS: We analyzed a total of 108 samples, 32 from patients treated with ipi/nivo and 76 with nivolumab only. No individual factor showed a significant association across both treatments. Some of the previously-reported biomarkers were found to be of prognostic significance in the ipi/nivo group, however, the findings could not be validated in the nivolumab cohort. When accounting for germline HLA-zygosity and TMB as a single predictor, we found that patients who were fully heterozygous at their HLA class-I loci and had tumors with high TMB, had a better PFS than homozygous patients (Cox, p[0.048, HR:1.72, ). This suggests that multiple factors are responsible for the likelihood of response to ICB therapy in ccRCC.
CONCLUSIONS: The predictors of response to combination immunotherapy may not be generalizable to the single-agent setting. No single factor could reliably predict response to therapy in metastatic ccRCC, multiple factors must be taken into account in order to understand ICB response. Renal cell carcinoma (RCC) incidence is increasing, and metastatic disease effects up to 25% of RCC patients. Additionally, RCC has varying prognoses and therapy responses, and metastatic RCC is incurable with a 5-year survival rate of <10%. An avatar model can be used for screening the best treatment for individual cancer patients. In this model, various drugs can be applied to determine the best outcome, by mimicking patient response in a xenograft model.
Our objective was to use an Avatar approach to compare the efficacy of various treatment combinations in alternating sequence in our unique patient-derived orthotopic xenograft (PDOX) model. METHODS: In our PDOX model, luciferase-tagged human RCC specimen cells (1Â10 5 KiCa-Pt58 cells or 3Â10 5 KiCa-Pt118 cells per mouse) were injected sub-capsularly into the left kidneys of NOD/ SCID mice. Mice bearing kidney tumors were randomized into 1 control or 4 sequential treatment groups receiving sunitinib (40 mg/ kg), pazopanib (40 mg/kg), or everolimus (5 mg/kg) three times per week via gavage (n[9-10). Tumor growth was monitored weekly by bioluminescent imaging (BLI). Drug responses were evaluated based on BLI data comparing treatment groups to control group and decisions made for mice that showed no inhibition of tumor growth to switch to the next sequence drug. All drugs were only changed once. Organs and tumors were collected upon necropsy for ex vivo BLI; tumor weights were recorded. Immunohistochemistry staining was done to confirm BLI findings.
RESULTS: Selected drug dosages delivered by gavage were safe, effective and without adverse effects. Drug sequence of pazopanib switch to everolimus is the best among 4 combinations tested for primary tumor progression and lung metastasis for patient tumor KiCaPt58, P[0.0059 and P[0.008, respectively; while sunitinib switch to everolimus is the best sequence among combinations tested for primary tumor progress for patient tumor KiCa-Pt118, P[0.0116.
CONCLUSIONS: Combination chemotherapies may prove to be advantageous for treating RCCs. When used alternatively, more favorable results were seen in regards to primary tumor growth and distant organ metastasis. Our results to date indicate that our PDOX model can be used to identify specific targeted and individualized therapeutic strategies, and that each RCC patient tumor cells responded to targeted treatment differently. Thus, individualized therapeutic strategies are required for RCC patients; An Avatar approach can effectively assist personalized therapy in RCC.
Source of Funding: Ochsner Health System

MP25-12 PREDICTORS OF MAJOR COMPLICATIONS AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: INSIGHTS FROM A RETROSPECTIVE MULTICENTRE REGISTRY
INTRODUCTION AND OBJECTIVES:
The role of cytoreductive nephrectomy (CN) in the setting of metastatic renal cell carcinoma (mRCC) is still object of great debate within the Urology community. In this regard, assessing the harms of CN is key to select patients most likely to benefit from this procedure.
The aim of the study was to evaluate potential predictors of major complications (MC) after CN in a multicentre international cohort of patients with mRCC.
METHODS: Data from patients with mRCC undergoing CN at 11 centers included in the REgistry of MetAstatic RCC (REMARCC) from January 2014 to December 2017 were retrospectively collected and analyzed. Patients with complete data on comorbidity profiles, intraoperative outcomes and perioperative complications formed the analytic cohort. Postoperative complications were assessed and graded using the modified Clavien-Dindo scale. MCs were defined as ClavienDindo grade 3 or more. Multivariable logistic regression analysiswas used to assess potential clinical predictors of 30-day readmission.
RESULTS: Overall, 374 patients were included in the study. Twenty-three patients (6.1%) experienced MCs. Patient age, sex, BMI, Charlson comorbidity index, ECOG performance status, baseline Hb levels, estimated glomerular filtration rate, cT and cN status, as well as location of metastatic lesions, were comparable among patients who did and did not experience MCs. Conversely, median tumor size was significantly higher in patients experiencing MCs (11.0 vs 8.5 cm, p[0.002). Surgical approach was significantly different in the two study groups (87.0% of patients who experienced MCs were treated with open CN as compared to 65.4% of patients who did not; p[0.034).
Performance of LDN was comparable among the study groups; on the contrary, removal of adjacent organs (43.5 % vs 23.4%, p[0.03), renal vein/vena cava thrombectomy (43.5% vs 17.4%, p[0.002) and metastasectomy at the time of CN (21.7% vs 7.1%, p[0.012) were significantly higher in patients who experienced MCs.
Rate of hospital readmission within 30 days after surgery was significantly higher in patients who experienced MCs (11.1% vs 6.7%, p<0.0001), as well as length of hospitalization (14 vs 7 days, p[0.003). pT status was also significantly different among the study groups (p[0.014).
At multivariable analysis, increasing tumor size, performance of metastasectomy at the time of CN and of renal vein/vena cava thrombectomy were found to be significantly associated with MCs in our study cohort.
CONCLUSIONS: Performance of metastasectomy and need for renal vein/vena cava thrombectomy may significantly impact on the risk of major complications after CN and should be carefully considered in the preoperative surgical planning. The main study limitation is the retrospective design with risk of selection and attrition bias. Antiangiongeniques) trial demonstrated that systemic therapy using sunitinib alone is not worse than cytoreductive nephrectomy (CN) plus sunitinib in metastatic RCC in an intention to treat analysis (hazard ratio HR): 0.89, 95% confidence interval (CI), 0.71-1.10). We wanted to assess patient views related to CN following the publication of these results.
Source of
METHODS: The Kidney Cancer Research Alliance (KCCure) conducted a survey among kidney cancer patients. The short survey was created via SurveyMonkey and was disseminated in various patient communities using social media and was posted to the KCCure website in June 2018 after the presentation of the CARMENA trial. Patients were asked "The CARMENA trial presented recently at ASCO found that for kidney cancer patients diagnosed with metastatic disease, there is no overall survival benefit of having a nephrectomy prior to starting systemic therapy. Knowing that information, would you still want to have a nephrectomy at diagnosis if you were metastatic?" Patients were also asked whether they had already had a nephrectomy and their stage at diagnosis, whether they were on systemic therapy, gender and age. RESULTS: n[210 patients responded with 60.5% being female. Median age 56.5 years (range 26-84). On the question of whether they would want CN. 75.2% of the patients indicated they would still
